Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Among authors: tan ec. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
Seino Y, Kim DJ, Yabe D, Tan EC, Chung WJ, Ha KH, Nangaku M, Node K, Klement R, Yasui A, Lei WY, Lee S, Kyaw MH, Deruaz-Luyet A, Brodovicz KG, H-H Sheu W; EMPRISE East Asia study group. Seino Y, et al. Among authors: tan ec. Endocrinol Diabetes Metab. 2020 Sep 16;4(1):e00183. doi: 10.1002/edm2.183. eCollection 2021 Jan. Endocrinol Diabetes Metab. 2020. PMID: 33532619 Free PMC article.
Healthcare resource utilization in patients treated with empagliflozin in East Asia.
Sheu WH, Seino Y, Tan EC, Yabe D, Ha KH, Nangaku M, Chung WJ, Node K, Yasui A, Lei WY, Lee S, Ustyugova A, Klement R, Deruaz-Luyet A, Kyaw MH, Kim DJ; EMPRISE East Asia study group. Sheu WH, et al. Among authors: tan ec. J Diabetes Investig. 2022 May;13(5):810-821. doi: 10.1111/jdi.13728. Epub 2022 Jan 11. J Diabetes Investig. 2022. PMID: 34859609 Free PMC article.
Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
Kim DJ, Sheu WH, Chung WJ, Yabe D, Ha KH, Nangaku M, Tan EC, Node K, Yasui A, Lei W, Lee S, Saarelainen L, Deruaz-Luyet A, Kyaw MH, Seino Y; EMPRISE East Asia Study Group. Kim DJ, et al. Among authors: tan ec. J Diabetes Investig. 2023 Mar;14(3):417-428. doi: 10.1111/jdi.13959. Epub 2023 Jan 30. J Diabetes Investig. 2023. PMID: 36716212 Free PMC article.
401 results